Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASAP DX
- Development stage
- Unknown
- Lead developer
- Anglo-French Drugs & Industries
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ASAP DX is an oral, small-molecule combination cough syrup developed by Anglo-French Drugs & Industries. It is formulated as a triple-combination therapy containing chlorpheniramine maleate (an antihistamine), dextromethorphan hydrobromide (a centrally acting cough suppressant), and phenylephrine hydrochloride (a nasal decongestant). ASAP DX is indicated for the symptomatic relief of dry allergic cough, common cold, hay fever, and associated upper respiratory allergy symptoms. Chlorpheniramine maleate acts as an antagonist at histamine H1 receptors to alleviate allergic symptoms such as sneezing and runny nose. Dextromethorphan hydrobromide acts as a sigma-1 receptor agonist and NMDA receptor antagonist in the brain's cough center to suppress the cough reflex. Phenylephrine hydrochloride acts as an agonist at alpha-1 adrenergic receptors to cause vasoconstriction in the nasal mucosa, thereby relieving nasal congestion.
- Brand names
- ASAP DXASAP DX Syrup
02
Targets
ADRA1A (α1A)HRH1 (Histamine H1 Receptor)NMDAR (Glutamate receptor ionotropic, NMDA)SIGMAR1 (Sigma non-opioid intracellular receptor 1)
Beyond the preview
Go deeper on ASAP DX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASAP DX.